1 Introduction The prevalence of type 2 diabetes mellitus (T2DM) has been on the rise globally in recent years, with data from the International Diabetes Federation (IDF) showing that there will be 783.2 million people (12.2%) living with diabetes by 2045 ( Standards of Care in Diabetes the addition of GLP-1RAs and/or SGLT2 inhibitors (SGLT2i) to the treatment plan for patients with T2DM who have been diagnosed with or are at high risk of atherosclerotic cardiovascular disease (ASCVD) ( However, the occurrence of gastrointestinal side effects (GISEs) has challenged the application of GLP-1RAs, which were clinically characterized by symptoms such as nausea (42.23%), vomiting (21.90%), diarrhea (21.93%), and constipation (8.41%) ( 2 Methods 2.1 Research design 2.1.1 Study participants and data sources The data used in the study were derived from the healthcare big data platform and the electronic medical record system of the First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
They are not licensed by the MHRA for human administration
In professional settings, healthcare providers may administer insulin to patients who are unable to self-inject or require assistance
The Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial is the first dedicated kidney outcome study specifically designed to assess the effect of a GLP-1 receptor agonist (once-weekly subcutaneous semaglutide) in people with type 2 diabetes mellitus and CKD at high-risk of progression (Table 1, Fig
The agency cited insufficient information about potential harm, immune reaction risks, contamination concerns, and lack of any approved indication
